Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Pain, Postoperative 5Breast Neoplasms 3Pain 2Colonic Neoplasms 2Supratentorial Neoplasms 1Stomach Neoplasms 1Sleep Deprivation 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Colorectal Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Surgery 1Breast Cancer Female 1Agnosia 1Abdominal Pain 1

Interventions

Vincristine 20Cytarabine 19Methotrexate 18Dexamethasone 17Cyclophosphamide 17Mercaptopurine 16Daunorubicin 12Asparaginase 12Doxorubicin 10Prednisolone 9Granulocyte Colony-Stimulating Factor 8Idarubicin 7Etoposide 7Thioguanine 6Teniposide 6Rituximab 6Prednisone 6Vindesine 5Ifosfamide 5Stem Cell Transplantation 4fludarabine 3Mitoxantrone 3Hydrocortisone 3pegaspargase 2Ketamine 2Inotuzumab Ozogamicin 2Imatinib Mesylate 2Cladribine 2Cholecalciferol 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Ropivacaine × Clear all
NCT06711679 2024-12-02

Exploring the Minimum Effective Concentration and Volume of Ropivacaine for Sacral Plexus Anesthesia

Tongji Hospital

Phase 4 Enrolling by invitation
180 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡